IL6 and COVID-19: Roactemra® (tocilizumab, an anti-IL6 antibody) has received specific regulatory approval for the treatment of COVID-19 in adults receiving systemic corticosteroid therapy and requiring oxygen supplementation or mechanical ventilation.